~~<i id='869A6D62D7'><strike id='869A6D62D7'><tt id='869A6D62D7'><pre id='869A6D62D7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

fashion

author：explore 2025-09-27 10:00:58 - browse：578

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： How to keep neuroscience’s past racism from being its future

focus

entertainment

hotspot

focus

knowledge

CourtesyBristolMyersSquibbBristolMyersSquibbwillpay$4.1billionforRayzeBio,thecompaniessaidTuesday,bu

WSS

What STAT readers think about the FDA and patient advocacy

Virtual care provider acquires bankrupt Pear's prescription apps

Violet CEO on training clinicians to promote more inclusive care

Christmas in the PICU brings some surprising joy

Violet CEO on training clinicians to promote more inclusive care

Christmas in the PICU brings some surprising joy

leisure time

fashion

focus

At least 13 dead in Texas as scorching temps continue

Christmas in the PICU brings some surprising joy

Drug repurposing or repositioning? The language matters

Why health care costs have stayed mostly flat since 2010

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why health care costs have stayed mostly flat since 2010

FDA approval of Sarepta Duchenne genetic therapy gives me hope

HCA sued by state AG for quality issues at Mission Health

entertainment

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Grail spinoff by Illumina should end disastrous merger attempt

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Medicare Advantage beneficiaries sue Humana over algorithm use

SNAP should offer more nutrition education

Editas, Vertex strike deal on CRISPR

hotspot

hotspot

focus

knowledge